Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 26/5/2017
SIETES contiene 91804 citas

 
 
 1 a 20 de 6374 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Curfman G. Risks of statin therapy in older adults. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101591]
2.Tiene citas relacionadas Cita con resumen
Han BH, Sutin D, Williamson JD, Davis BR, Piller LB, Pervin H, Pressel SL, Blaum CS, for the ALLHAT Collaborative Research Group. Effect of statin treatment vs usual care on primary cardiovascular prevention among older adults. The ALLHAT-LLT randomized clinical trial. JAMA Intern Med 2017:22 de mayo. [Ref.ID 101590]
3.Enlace a cita original Cita con resumen
Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]
4. Cita con resumen
Anónimo. Drugs for hypertension. The Medical Letter on Drug and Therapeutics Bulletin 2017;59:41-8. [Ref.ID 101527]
5.Tiene citas relacionadas Cita con resumen
Grosser T. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2017;376:1389-90. [Ref.ID 101526]
6. Cita con resumen
Prada-Ramallal G, Takkouche B, Figueiras A. Diverging conclusions from the same meta-analysis in drug safety: source of data (primary versus secondary) takes a toll. Drug Saf 2017;40:351-8. [Ref.ID 101501]
7.Enlace a cita original Cita con resumen
Stolk LM, de Vries F, Ebbelaar C, de Boer A, Schalekamp T, Souverein P, ten Cate-Hoek A, Burden AM. Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. Br J Clin Pharmacol 2017:marzo. [Ref.ID 101480]
9. Cita con resumen
Chobanian AV. Hypertension in 2017- What is the right target?. JAMA 2017;317:579-80. [Ref.ID 101415]
10.
Felson DT. Safety of nonsteroidal antiinflammatory drugs.. N Engl J Med 2016;373:2595-6. [Ref.ID 101348]
11.Tiene citas relacionadas Cita con resumen
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, Graham DY, Borer JS, Wisniewski LM, Wolski KE, Wang Q, Menon V, Ruschitzka F, Gaffney M, Beckeman B, Berger MF, Bao W, Lincoff AM, for the PRECISION Trial Investigators. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;373:2519-29. [Ref.ID 101038]
12.Enlace a cita original Cita con resumen
Zong G, Li Y, Wanders AJ, Alssema M, Zock PL, Willett WC, Hu FB, Sun Q. Intake of individual saturated fatty acids and risk of coronary heart disease in US men and women: two prospective longitudinal cohort studies. BMJ 2016;355:i5796. [Ref.ID 100999]
13. Cita con resumen
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T, for the SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44. [Ref.ID 100972]
14. Cita con resumen
Gargiulo G, Windecker S, da Costa BR, Feres F, Hong M-K, Gilard M, Kim H-S, Colombo A, Bhatt DL, Kim B-K, Morice M-C, Park KW, Chieffo A, Palmerini T, Stone GW, Valgimigli M. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ 2016;355:i5483. [Ref.ID 100878]
15.Tiene citas relacionadas Cita con resumen
Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif J-C, Tendera M, Tavazzi L, Bhatt DL, Steg PG, CLARIFY Investigators. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet 2016;388:2142-52. [Ref.ID 100862]
17.Enlace a cita original Cita con resumen
Patrono C. Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. Br J Clin Pharmacol 2016;82:957-64. [Ref.ID 100827]
18. Cita con resumen
Graham DJ, Reichman ME, Wernecke M, Hsueh Y-H, Izem R, Southworth MR, Wei Y, Liao J, Goulding MR, Mott K, Chillarige Y, MaCurdy TE, Worrall C, Kelman JA. Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 2016:3 de octubre. [Ref.ID 100779]
19. Cita con resumen
Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA 2016;316:1289-97. [Ref.ID 100769]
20.Tiene citas relacionadas Cita con resumen
Larsen TB, Nielsen PB. Stroke and mortality after atrial fibrillation—a global struggle. Lancet 2016;388:1131-2. [Ref.ID 100749]
Seleccionar todas
 
 1 a 20 de 6374 siguiente >>